Description
ADCC-enhanced iodine (124I) girentuximab is a non-fucosylated anti-CA9 therapeutic biobetter antibody.
Antibody Indication
Kidney tumours
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced CA9 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Alternative Names
CA9; carbonic anhydrase IX; carbonic anhydrase 9; CAIX; carbonic dehydratase; MN; RCC associated protein G250; pMW1; CA-IX; P54/58N; membrane antigen MN; carbonate dehydratase IX; RCC-associated antigen G250;
Cellular Localization
Plasma membrane, Nucleus
Involvement in Disease
Diseases associated with CA9 include Sarcomatoid Renal Cell Carcinoma and Clear Cell Renal Cell Carcinoma.
Related Pathways
Its related pathways are Celecoxib Pathway, Pharmacodynamics and Metabolism.
Function
Reversible hydration of carbon dioxide. Participates in pH regulation. May be involved in the control of cell proliferation and transformation. Appears to be a novel specific biomarker for a cervical neoplasia.
Post-translational modifications
Asn-346 bears high-mannose type glycan structures.
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Clone
iodine (124I) girentuximab
Description
Recombinant antibody to Human CA9. The drug candidate REDECTANE® (INN: 124I-Girentuximab) is based on an antibody and is being developed for the pre-surgical diagnosis of clear cell Renal Cell Cancer. REDECTANE® is the radioactively labelled form of the antibody Girentuximab. The monoclonal antibody Girentuximab binds specifically to a protein structure on the cell surface of malignant tumour cells. This protein structure, called Carbonic anhydrase IX (also CA-IX, MN or G250 antigen) is found on over 90 % of clear cell renal cell carcinomas, but not on normal renal tissue.
Antibody Indication
Kidney tumours
